Evaluation of the humoral response during ocrelizumab therapy in multiple sclerosis — an observational study
Neurologia i Neurochirurgia Polska · 21.07.2026
DOI: 10.5603/pjnns.108289 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurologia i Neurochirurgia Polska, online erschienen am 21.07.2026. Verfasst von Joanna Rychter und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Medical University of Warsaw, Poland.
Abstract (Originalsprache)
Introduction
Anti-CD20 monoclonal antibodies are widely used as high-efficacy treatment agents (HETAs) in multiple sclerosis (MS). In patients treated with ocrelizumab (OCR), reduced serum IgG levels are a common laboratory abnormality. Infections are among the most frequently observed adverse events during OCR therapy. Material and methods. We analyzed the humoral immune response during OCR therapy in 52 people with multiple sclerosis (PwMS) and assessed the safety of this treatment, including treatment-related adverse events and infection rates over a period of up to six years.
Results
After three years of treatment, immunoglobulin G (IgG) and IgG1 levels decreased, particularly in the relapsing-remitting MS (RMS) group. Higher body mass index (BMI) was associated with lower Ig levels and greater CD19+ cell depletion. Infections were more frequent in patients with relapses within 3 months prior to OCR initiation. Clinical implications/future directions. Ocrelizumab treatment for up to six years showed a manageable safety profile. Given the higher infection risk in patients with greater disease activity, earlier HETA initiation may be beneficial. The association between higher BMI and CD19+ cell depletion warrants further study to support personalized OCR dosing strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Medical University of Warsaw, Poland.
- Department of Neurology, Medical University of Warsaw, Poland. apodlecka@wum.edu.pl.
- Department of Medical Informatics and Telemedicine, Medical University of Warsaw, Poland.
ORCID-Profile: Aleksandra Podlecka-Piętowska, Janusz Sierdziński, Beata Zakrzewska-Pniewska, Monika Nojszewska
Zitieren
APA
Rychter, J., Podlecka-Piętowska, A., Sujkowska, K., Sierdziński, J., Zakrzewska-Pniewska, B., & Nojszewska, M. (2026). Evaluation of the humoral response during ocrelizumab therapy in multiple sclerosis — an observational study. Neurologia i Neurochirurgia Polska. https://doi.org/10.5603/pjnns.108289
Vancouver
Rychter J, Podlecka-Piętowska A, Sujkowska K, Sierdziński J, Zakrzewska-Pniewska B, Nojszewska M. Evaluation of the humoral response during ocrelizumab therapy in multiple sclerosis — an observational study. Neurologia i Neurochirurgia Polska. 2026. doi:10.5603/pjnns.108289
BibTeX
@article{Rychter2026,
author = {Rychter, Joanna and Podlecka-Piętowska, Aleksandra and Sujkowska, Kinga and Sierdziński, Janusz and Zakrzewska-Pniewska, Beata and Nojszewska, Monika},
title = {Evaluation of the humoral response during ocrelizumab therapy in multiple sclerosis — an observational study},
journal = {Neurologia i Neurochirurgia Polska},
year = {2026},
doi = {10.5603/pjnns.108289}
}
EUVIMED